STOCK TITAN
  1. Home
  2. News
  3. BMRA

BIOMERICA INC - $BMRA STOCK NEWS

Welcome to our dedicated page for BIOMERICA news (Ticker: $BMRA), a resource for investors and traders seeking the latest updates and insights on BIOMERICA stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOMERICA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOMERICA's position in the market.

News
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
Rhea-AI Summary

Biomerica Inc. (Nasdaq: BMRA) announced an exclusive distribution agreement with a UAE healthcare conglomerate for their at-home screening products, EZ Detect™ for colorectal cancer and Aware® for breast exams. The Dubai Healthcare Authority approved insurance reimbursement for EZ Detect™, enhancing accessibility. The partnership aims to integrate these tests into national health protocols, with potential for introduction of more Biomerica products in the UAE. EZ Detect™ simplifies colorectal screening by detecting occult blood in stool, revolutionizing at-home testing. Aware® increases tactile sensitivity during breast self-exams, important for early breast cancer detection. The collaboration signifies a step towards proactive health management in the Middle East, with a focus on reducing the burden of cancer through early detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.95%
Tags
none
-
News
Biomerica provides update on inFoods® IBS expansion
Rhea-AI Summary
Biomerica, Inc. (BMRA) announces significant advancements in the expansion of the inFoods IBS product, including new office locations and increased physician engagement. The company has seen a substantial increase in the number of physicians prescribing inFoods, with discussions underway for collaboration with non-GI physician groups. Additionally, Biomerica has received notices of allowance for five new patents in Europe, Canada, and Japan, bringing the total to 25 patents for the inFoods technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
none
-
News
Biomerica Reports Third Quarter 2024 Financial Results
Rhea-AI Summary
Biomerica, Inc. (BMRA) reports third-quarter 2024 financial results, showing improvement with a narrowed loss per share of $0.27 from $0.40. The company expands its sales force and presents positive clinical data for InFoods IBS at the upcoming Digestive Disease Week 2024 Conference. Biomerica is in discussions with key clinical lab customers for the use of its FDA-cleared Hp Detect™ Test to detect H. pylori bacteria.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
earnings
News
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Rhea-AI Summary
Biomerica, Inc. (BMRA) collaborates with the University of Michigan to present new data on InFoods® IBS technology at the 2024 Digestive Disease Week. The groundbreaking technology showcases potential novel dietary interventions for IBS sufferers, contributing valuable clinical evidence supporting its efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
none
-
News
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
Rhea-AI Summary
Biomerica, Inc. appoints former LabCorp Diagnostics CEO, Gary Huff, to its Strategic Advisory Board. Mr. Huff's extensive experience in medical diagnostics and healthcare, overseeing a $7B diagnostics clinical laboratory, will drive the expansion of Biomerica's inFoods IBS and FDA-cleared HP Detect products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
management
-
News
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
Rhea-AI Summary
Biomerica, Inc. (NASDAQ: BMRA) appoints Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., as the Chairman of the Board of Directors. Mr. Kenny's extensive experience and successful track record in medical diagnostics and healthcare, including the $1.53 billion sale of Meridian Bioscience, are expected to bring valuable insights and expertise to Biomerica.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
none
News
Biomerica Reports Second Quarter 2024 Financial Results
Rhea-AI Summary
Biomerica, Inc. reported a 10.3% increase in revenues excluding Covid test sales for the second fiscal quarter of 2024 compared to the same period in 2023. The loss per share narrowed to $0.09 from $0.12 due to disciplined operating expense management. The company also received US FDA 510(k) clearance for its Hp Detect™ ELISA Test Product designed to detect the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population. The product is marketed to clinical labs in the US and internationally. The company also expanded its reach with the addition of new GI groups. The financial results for the second quarter of fiscal 2024 showed a 6.7% increase in net sales compared to the same period in 2023, with a 20.7% gross margin. Operating expenses improved to $1.9 million from $2.0 million in the prior year, and the company had cash and equivalents of $7.1 million as of November 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
earnings
-
News
Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population
Rhea-AI Summary
Biomerica, Inc. (BMRA) has received FDA 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test to detect H. pylori bacteria, which infects 35% of the U.S. population. The test can diagnose H. pylori presence, crucial for assessing status after treatment, especially in the context of increasing antibiotic resistance. Over 80% of gastric cancers are attributed to H. pylori infection, making this FDA clearance a milestone in providing a diagnostic solution for over 115 million people suffering from H. pylori infection across the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
66.67%
Tags
clinical trial
-
News
Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16
Rhea-AI Summary
Biomerica, Inc. (BMRA) to participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, in New York City. CEO Zackary Irani to host one-on-one and small group meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
conferences
News
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups
Rhea-AI Summary
Biomerica (BMRA) remains on track for inFoods® IBS national rollout in 2024, expecting strong product revenue growth. New GI groups have signed up for the inFoods IBS product, demonstrating growing recognition and adoption in the medical community, positioning the company for growth. Clinical trials have shown significant improvement in IBS patients using the product, with notable outcomes comparable to FDA cleared drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.59%
Tags
none
Stock BMRA logo
BIOMERICA INC

Nasdaq:BMRA

BMRA Rankings

N/A Ranked by Market Cap
#5099 Ranked by Stock Gains
N/A Ranked by Dividends

BMRA Stock Data

9.92M
15.59M
7.3%
26.73%
0.4%
Dental Equipment and Supplies Manufacturing
Manufacturing
Link
United States of America
IRVINE

About BMRA

biomerica, inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. the company’s products are designed to enhance health and well-being, while reducing total healthcare costs. biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. the biomerica infoods® ibs product identifies patient specific foods that when removed may alleviate an individual's ibs symptoms. this patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve irritable bowel syndrome (ibs) outcomes. the point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for wh